Devices and methods can be used to treat dermatologic disorders using low dose DC electroporation. Such electroporation is essentially non-thermal modulation. In some implementations, the devices and methods described herein can be used for anti-aging treatments. In some implementations, the devices and methods described herein can be used for detecting/screening of various types of skin cancers. In some implementations, the devices and methods described herein can be used for therapy delivery for the treatment of early or pre-malignant skin cancers.

A method of treating connective tissue by applying a DC current to the tissue in the absence of intentionally heating the tissue.

In alternative embodiments, provided are products of manufacture and kits, and methods, for hydrogen and hydrogen peroxide generation, and for the treatment of diseases, conditions and infections responsive to exposure to a therapeutic amount of hydrogen, metastable hydrogen peroxide and/or oxygen treatment; including providing a hydrogen, metastable hydrogen peroxide and/or oxygen treatment or delivery system for cosmetic purposes.

A method and device for electroporating adipocytes in the adipose layer of tissue, where the device includes a frame, a first electrode coupled to the frame having a first contact surface, a second electrode coupled to the frame having a second contact surface, and where the first contact surf ace and the second contact surface define a treatment zone therebetween. The method including positioning a fold of tissue between the first and second electrodes such that the treatment zone formed between the two electrodes includes an adipose layer of tissue and no skeletal muscle.

A device with in situ anode and cathode microneedles is used, either with or without any cosmetic, cosmeceutical, nutraceutical, and/or pharmaceutical composition or formulation. The in situ anode and cathode microneedles form battery cells or half-cells when placed in contact with an electrolyte found in bodily interface tissue, to produce an electromotive force without any additional chemical battery or power source. The microneedles may be composed of, or may carry (e.g., be coated with) electrical potential material(s) that has or have an electrical potential relative to an electrolyte in the bodily interface material. A first number of microneedles may, for instance, include a first electrical potential material having a first electrical potential. A second number of microneedles may, for instance, include a second electrical potential material having a second electrical potential. The first number of microneedles may thus serve as an anode, while the second number of microneedles may thus serve as a cathode. Alternatively, a number of microneedles may, for instance, include both a first electrical potential material and a second electrical potential material, having a first electrical potential and a second electrical potential, respectively. Respective portions of each of the microneedles may thus serve as an anode and a cathode. Again, such may be accomplished without any other or additional electrochemical battery.

The present invention relates to a therapeutic device which comprises: an endoscope channel; and an electrode that can be inserted into a human body through the endoscope channel, wherein the electrode destroys a target cell in the human body through voltage application, and the electrode includes a first optical fiber and a second optical fiber for detecting the degree of destruction of the target cell through impedance measurement. In addition, the present invention relates to a therapeutic device employing an endoscope-interworking electrode which comprises: an endoscope channel; and a catheter that can be inserted into a human body through the endoscope channel, wherein the catheter comprises a perforated portion provided on an end thereof, which is inserted into the human body, and a plurality of electrodes that can protrude from the end of the catheter through the perforated portion to penetrate a target cell.

Devices and methods for delivering an electropermeabilizing pulse of electric energy to a tissue surface to enable delivery into cells in the tissue therapeutic substances. The device incorporates a source capable of generating a sufficient voltage potential to deliver a spark across a gap and delivers same to the tissue surface.

A system for treating infected tissue includes an applicator device. The applicator device has an electrode pair spaced apart and is positioned against infected tissue. An electrical power supply to generate a pulsed electric field across the electrode pair, resulting in the application of a pulsed electric field through the infected tissue. The pulsed electric field has a field strength within a range that when the pulsed electric field is applied, pores are formed in membranes of cells of the infected tissue. A method for treating infected tissue is disclosed. The method includes positioning an electrode pair against the infected tissue; applying a pulsed electric field across the electrode pair. The pulsed electric field has a field strength that when applied, pores are formed in membranes of cells of the infected tissue; and applying an antimicrobial agent into or onto the infected tissue when the pulsed electric field is applied.

Biological cell destruction is achieved through a combination of injection of a substance and application of an electrical field. The substance, such as a cationic polymer, is selected for its electrical characteristics which can add to the transmembrane electric field of a cell when the electrical field is applied. In some examples, electrical field application is performed to encourage spatial concentration of the injected substance favorable to increased transmembrane field strength. The biological cell or cells are destroyed primarily through irreversible electroporation.

An oral appliance for the treatment of sleep disorders, such as obstructive sleep apnea, in a user is presented. The oral appliance may include a mouthpiece configured to receive a user's dentition. The mouthpiece may include an oxygen sensor, a pressure sensor, an airflow sensor, an actigraphy sensor, a noise detector, and at least one stimulator for providing stimulation to a user's tongue in the event of decreased oxygen saturation levels, increased pressure applied to occlusal surfaces of the user's dentition, decreased actual airflow levels and/or increased noise levels. The mouthpiece may be provided with pharmaceutical compound reservoirs that deliver pharmaceutical compounds to the oral mucosa of the user, which compounds treat symptoms of sleep apnea. The mouthpiece may further include a microprocessor that receives data from the oxygen sensor, pressure sensor, airflow sensor, actigraphy sensor and noise detector, and activates the at least one stimulator and/or pharmaceutical compound reservoirs.